FDA Grants Authorization for New Pancreatic Cancer Medication

Buzzline

The Food and Drug Administration has given the green light to Rasonque, also referred to as daraxonrasib, a daily oral medication aimed at adults suffering from metastatic pancreatic adenocarcinoma whose condition has advanced following prior therapies. In a phase 3 clinical trial with 500 participants, those treated with daraxonrasib had an average survival of 13.2 months, compared to 6.7 months for those receiving chemotherapy. This drug specifically addresses RAS mutations, which are present in over 90% of pancreatic cancer cases. Common adverse effects consist of nausea, skin rash, and diarrhea, with rare but serious risks including pneumonitis. Additional studies will explore its application in earlier treatment stages and for other types of cancer. Disclosure:This video contains stock footage and content created or enhanced using Ai-assisted tools ai-generated

Transcript

00:00Rasank, a newly FDA-approved drug, is offering a new treatment option for advanced pancreatic cancer.

00:06The daily pill is designed for adults whose cancer has progressed after earlier treatments.

00:12The approval is based on a Phase III clinical trial involving 500 patients.

00:17Patients receiving Daraxin-Raseb lived an average of 13.2 months.

00:21Those receiving chemotherapy survived an average of 6.7 months.

00:25That means the drug more than doubled average survival compared with chemotherapy.

00:30Daraxin-Raseb works by targeting RAS mutations that drive cancer cell growth.

00:35These mutations are found in more than 90% of pancreatic cancer cases.

00:40The treatment could provide an important second-line option for patients with limited choices.

00:45Most participants tolerated the drug well, although side effects can include nausea, rash, and diarrhea.

00:52Doctors also warn of a rare but potentially fatal lung inflammation called pneumonitis.

00:56Further clinical trials will examine whether Rasank can be used earlier in treatment.

01:02Disclosure.

01:02This video contains stock footage and content created or enhanced using AI-assisted tools, AI-generated.

01:08Disclosure.

Category

Transcript

Comments

Recommended